Caribou Biosciences, Inc. Earnings Per Share Disclosure
| Years Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Numerator: | |||||||||||
| Net loss | $ | (149,105) | $ | (102,070) | |||||||
| Denominator: | |||||||||||
| Weighted-average common shares outstanding used to compute net loss per share, basic and diluted | 90,317,925 | 73,807,597 | |||||||||
| Net loss per share, basic and diluted | $ | (1.65) | $ | (1.38) | |||||||
| As of December 31, 2024 | As of December 31, 2023 | ||||||||||
| Stock options outstanding | 10,782,103 | 9,410,404 | |||||||||
RSUs issued and outstanding | 1,297,327 | 153,000 | |||||||||
Shares committed under ESPP | 304,434 | 134,276 | |||||||||
| 12,383,864 | 9,697,680 | ||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 10, 2025 | Showing above |
| 2022 | Mar 9, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.